Update: Transmission of HIV-1 from mother to child

Current Opinion in Infectious Diseases

Volumn 10, Issue 6, 1997, Pages 496-501

  Fowler, Mary Glenn ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

AMNIOCENTESIS; BIRTH; BREAST FEEDING; CESAREAN SECTION; COHORT ANALYSIS; DELIVERY; FEMALE; FETUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE RUPTURE; MOTHER; NEWBORN; PLACENTA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREGNANCY; PREMATURE LABOR; PRENATAL PERIOD; PUBLIC HEALTH; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 0030862443     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199712000-00016     Document Type: Review

References (33)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL et al. for the Pediatric AIDS Clinical Trail Group Protocol 076 Study Group: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
2. UNAIDS Fact Sheet: HIV/AIDS: The Global Epidemic. Geneva: UNAIDS December 1996.
3. Centers for Disease Control: US Public Health Service Task Force recommendations for use of antiretroviral drugs during pregnancy for maternal health and reduction of perinatal transmission of human immunodeficiency virus type 1 in the United States. MMWR 1994, 43 (RR-11):1-20.
4. Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, Boyer PJ, Keller M, Deveikis A, Stiehm R, Bryson Y: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996, 275:599-605.
5. Fang G, Burger H, Grimson R, Tropper P, Nachman S, Mayers D, Weislow O, Moore R, Reyelt C, Hutcheon N et al.: Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995, 92:12100-12104.
6. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry G, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996, 335:1621-1629. This analysis of plasma viral RNA data from the successful zidovudine clinical trial ACTG 076 provides critical and informative data on the general correlation of maternal viral load with the risk of perinatal transmission, but also demonstrates that transmission can occur at all levels (including non-detectable levels). The study also demonstrated that viral load reduction only partly explained the effect of the zidovudine intervention, and that zidovudine was protective at all levels of maternal plasma RNA.
7. Mayaux MJ, Dussaix E, Isopet J, Rekacewicz C, Mandelbort L, Ciraru-Vigneron N, Allemon MC, Chambrin V, Katlama C, Delfraissy JF, Puel J for the SEROGEST Cohort Group: Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. J Infect Dis 1997, 175:172-175.
8. Cao Y, Krogstad P, Korber BT, Koup RA, Muldoon M, Macren C, Song JL, Jin Z, Zhao JQ, Clapp S et al, and the Ariel Project Investigators: Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997, 3:549-552.
9. Thea DM, Steketee RW, Pliner V, Bornschlegel K, Brown T, Orloff S, Matheson PB, Abrams EJ, Bamji M, Lamber G et al. and the New York City Perinatal HIV Transmission Collaborative Study Group: The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS 1997, 11:437-444. This paper confirms a general association of increased maternal viral load with the risk of mother-to-infant transmission, and also suggests that women with the highest CD4 counts might benefit most from zidovudine use for the prevention of HIV transmission.
10. Jackson JB, Horn D, Piwowar E, Ndugwa C, Kataaha P, Marum L, Guay L, Parsons J, Olness K, Mmiro F: Maternal HIV-1 RNA serum levels at delivery and vertical transmission in Uganda. Pediatr AIDS HIV Infect 1996, 7:37-42.
11. Burns DN, Landesman S, Wright DJ, Waters D, Mitchell RM, Rubinstein A, Willoughby A, Goedert JJ: Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997, 175:1206-1210.
12. Burchett SK, Kornegay J, Pitt J, Landsman S, Rosenblatt H, Hillyer G, Garcia P, Kalish L, Burns D, Davenny K, Lew J for the Women and Infants Transmission Study: Assessment of maternal plasma HIV viral load as a correlate of vertical transmission. Proceedings of the Third Conference of Retroviruses and Opportunistic Infections. Washington DC; January 23-February 1, 1996:LB3, p.161.
13. Pediatric ACTG Protocol 185 Executive Summary: National Institute of Child Health and Human Development, National Institutes of Health, Bethesda MD: March 1997.
14. Schaffer N, Chotpitaryasunondh T, Roongpisssuthipong A, Siriwasin W, Chearskkul S, Youg N, Brown T, Nieburg P, Batter V, Kalish ML, Mastro TD: High maternal viral load predicts perinatal HIV-1 transmission and early infant progression, Bangkok, Thailand. Proceedings of the Third Conference of Retroviruses and Opportunistic Infections [abstract 30]. Washington DC, January 23-February 1, 1996 :58.
15. Landesman SH, Kalish LA, Burns DN, Minkoff H, Fox HE, Zorrilla C, Garcia P, Fowler MG, Mofenson L, Tuomala R for the Women and Infants Transmission Study: Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996, 334:1617-1623. This paper assessed that membrane rupture of more than 4 h duration was associated with a doubling of the risk of perinatal transmission after adjustment for other cofactors. The data were gathered among a cohort of HIV-infected pregnant women before the widespread use of zidovudine for the prevention of perinatal transmission.
16. Kuhn L, Abrams EJ, Matheson PB, Thomas PA, Lambert G, Bamji M, Greenberg B, Steketee RW, Thea DM and the New York City Perinatal HIV Transmission Collaborative Study Group: Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS 1997, 11:429-435.
17. Minkoff H, Burns DN, Landesman S, Youchah J, Goedert JJ, Nugent RP, Muenz L, Willoughby A: The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995, 173:585-589.
18. Mandelbrot L, Mayaux MJ, Bongain A, Berrebi A, Mooudoub-Jenpetit Y, Benifla JL, Ciraru-Vigneron N, Le Chenadec J, Blanche S, Delfraissy JF and the French Pediatric HIV Infection Study Group: Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. Am J Obstet Gynecol 1996, 175:661-667. This large French epidemiological study of 1632 HIV-1-infected mothers and their infants evaluated obstetrical factors in relation to the risk of mother-to-child HIV transmission. Findings were that amniocentesis and amnioscopy, the presence of sexually transmitted diseases, preterm delivery, the premature rupture of membranes, and hemorrhage during labor or bloody amniotic fluid were all associated with an increased risk of perinatal transmission.
19. The European Collaborative Study: Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS 1996, 10:1675-1681.
20. Tovo PA, de Martino M, Gabiano C, Galli L, Cappello N, Ruga E, Tulisso S, Vierucci A, Loy A, Zuccotti GV et al. and the Italian Register for HIV Infection in Children: Mode of delivery and gestational age influence perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 1996, 11:88-94.
21. Bobat R, Hoosen C, Coutsoudis A, Moodley D: Determinants of mother-to-child transmission of human immunodeficiency virus type 1 infection in a cohort from Durban, South Africa. Pediatr Infect Dis J 1996, 15:1604-1610.
22. Kaneda T, Shiraki K, Hirano K, Nagata I: Detection of maternofetal transfusion by placental alkaline phosphatase levels. J Pediatr 1997, 130:730-735.
23. Popeck EJ, Korber BT, Merritt L, Bardenguez A, Luzuriaga K, Van Dyke RB for the Ariel Project Cohort Research Group: Acute chorioamnionitis and duration of membrane rupture correlates with vertical transmission of HIV-1. Proceedings of the Fourth Conference on Retroviruses and Opportunistic Infections [abstract 504]. January 1997; Washington DC:158.
24. St Louis ME, Kamenga M, Brown C, Nelson AM, Manzila T, Batter V, Behets F, Kabagago U, Ryder RW, Oxtoby M et al.: Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic and placental factors. JAMA 1993, 269:2853-2859.
25. Burton GJ, O'Shea S, Rostron T, Mullen JE, Aiyer S, Skepper JN, Smith R, Banatvala JE: Significance of placental damage in vertical transmission of human immunodeficiency virus. J Med Virol 1996, 50:237-243.
26. Bertolli J, St Louis ME, Simonds RJ, Nieburg P, Kamenga M, Brown C, Tarande M, Quinn T, Ou CY: Estiminating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J. Infect Dis 1996, 174:722-726. The proportion of perinatal HIV infection occurring during the in-utero, intrapartum/early postpartum, and late postnatal period was estimated on the basis of the timing of the first positive PCR, culture or serology among 69 infected infants from Kinshasa, Zaire. The authors estimate that 23% were infected in utero, 65% during the intrapartum/early postpartum period, and only 12% during the late postpartum period from breast feeding.
27. Ekpini ER, Wiktor SZ, Satten FA, Adjorlolo-Johnson GT, Sibailly TS, Ou CY, Karon JM, Brattegaard K, Whitaker JP, Gnaore E et al.: Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire. Lancet 1997, 349:1054-1059.
28. Nduati RW, John GC, Richardson BA, Overbaugh J, Welch M, Ndinya-Achola J, Moses S, Holmes K, Onyango F, Kreiss JK: Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis 1995, 172:1461-1468.
29. Guay LA, Hom DL, Mmiro F, Piwowar ES, Kabengera S, Parsons J, Ndugwa C, Marum L, Olness K, Kataaha P, Jackson JB: Detection of human immunodeficiency virus type 1 (HIV-1) DNA and p24 antigen in breast milk of HIV-1-infected Ugandan women and vertical transmission. Pediatrics 1996, 98:438-444. In a perinatal cohort study from Uganda, the duration of breast feeding was not significantly different between women who transmitted HIV to their infants and those who did not, and no correlation was found between the detection of HIV-1 in breast milk, on the basis of DNA PCR or immune complex dissociated p24 antigen.
30. Rouzioux C, Costaglioloa D, Burgard M: Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. Am J Epidemiol 1995, 142:1330-1337.
31. Mandelbrot L, Brossard Y, Aubin JT, Bignozzi C, Krivine A, Simon F, Dommergues M: Testing for in utero human immunodeficiency virus infection with fetal blood sampling. Am J Obstet Gynecol 1996, 175:489-493.
32. Kalish L, Pitt J, Lew J, Landesman S, Diaz, C, Hershow R, Hollinger FB, Pagano M, Smeriglio V, Moye J for the Women and Infants Transmission Study (WITS): Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. J Infect Dis 1997, 175:712-715.
33. Dunn DT, Brandt CD, Krivine K, Cassol SA, Roques P, Borkowsy W, De Rossi A, Denamur E, Ehrnst A, Loveday C et al.: The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995, 9:F7-F11.